CSL’s healthy result

Australia’s largest pharmaceutical company, CSL Limited (ASX: CSL) with a market cap of more than $29 billion, has reported a 24% rise in first-half profits as demand for its blood products soars. Net profit came in at US$627 million, while earnings per share jumped 30% to SU124.7 cents, thanks to the effect of the company’s ongoing share buyback.

Showing that the company is also increasing its margins, and becoming more efficient, sales only rose 7% to US2.5 billion. CSL increased the interim dividend to 50 cents per share, unfranked.

Looking at specific product performance, immunoglobulin sales grew 10% to US912 million, while haemophilia product sales rose to US$542 million. Other human health sales climbed by 19% to US$518 million on the back of increased demand for plasma therapies and influenza sales.

Looking forward, the company expects to report profit growth of around 20% for the full 2013 financial year, barring any unforeseen variables. Earnings per share growth will exceed profit growth again, as the company is still only 21% of the way through a $900 million share buyback.

The company continues to invest in research and development, and has a number of studies underway, which if successful should continue to support high levels of growth.

Foolish takeaway

Australian pharmaceutical and healthcare companies continue to impress globally, including CSL, Cochlear Limited (ASX: COH), Acrux Limited (ASX: ACR) and Mesoblast (ASX: MSB). That shows the strength of our biotechnology industry, although not every company is guaranteed success.

Oil, copper, and gold continue to be in high-demand — and their popularity doesn’t look to be slowing. We’ve uncovered three companies poised to benefit from the rising prices of these commodities. Get our brand-new report — “3 High-Risk/High-Reward Resources Stocks” — FREE!

More reading

The Motley Fool’s purpose is to help the world invest, better.   Click here now  for your free subscription to Take Stock, The Motley Fool’s free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead.  This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. Motley Fool writer/analyst Mike King owns shares in CSL and Cochlear.

5 Companies we like better than

When ace stock picker Scott Phillips has a buy recommendation, history suggests it can pay to listen.

Scott recently revealed what he believes are the five best ASX stocks for investors to buy right now... and wasn't one of them! That's right -- he thinks these 5 stocks are even better buys.

Learn more

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.